NDAORALTABLET
Approved
Aug 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
ELLA (ulipristal acetate) by Teva is occur, ella postpones follicular rupture. Approved for uterine leiomyoma, uterine hemorrhage, emergency contraception. First approved in 2010.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELLA (ulipristal acetate) is an oral selective progesterone receptor modulator indicated for emergency contraception and uterine disorders including leiomyoma, hemorrhage, and adenomyosis. It works primarily by inhibiting or delaying ovulation, with possible secondary effects on endometrial alterations that may affect implantation.
$0.741MPart D
Peak4.1 years to LOEProduct is at peak commercial maturity with stable but limited Part D claims, suggesting a niche market with moderate team investment from Teva.
Mechanism of Action
occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy.
Indications (3)
Worked on ELLA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.